The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
about
Development and Function of Protective and Pathologic Memory CD4 T CellsMucosal resident memory CD4 T cells in protection and immunopathologyThe evolution of poxvirus vaccinesImmunoregulatory functions and expression patterns of PE/PPE family members: Roles in pathogenicity and impact on anti-tuberculosis vaccine and drug designIncreased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis AntigenR&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014.The influence of delivery vectors on HIV vaccine efficacyProtection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine EfficacyProgress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans.A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune ResponsesAcquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus.Strategies to improve BCG vaccine efficacy.The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.Towards new TB vaccines: What are the challenges?Increasing Complexity of Vaccine Development.A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.Adenylate kinase: a novel antigen for immunodiagnosis and subunit vaccine against tuberculosis.A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.Polyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationPrevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.The current status, challenges, and future developments of new tuberculosis vaccines.A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
P2860
Q26781324-59C2D499-4610-4F91-8E76-92D40B285B99Q26823137-B86A7A2A-229C-4FF9-9F2D-8D68D24AAC00Q26995905-E4C3D6D6-69AF-4AF9-A672-63DDF98A1058Q27013243-83193B45-02C5-4EE0-9B15-8B6E523503E3Q27302995-FB057676-FF81-4C6E-8EBC-77D9FF981BA9Q30379192-0C910919-80D7-4905-A125-E04FFCFFE83CQ34077543-C6EEE31A-A532-4402-939C-704022BD882DQ35231023-8F01052C-B73E-4876-929A-AF94BC5C0866Q35782951-D165D244-1DA0-4542-9451-ECCC8AF37BC4Q36219941-A760FB28-8B45-44E3-8847-400B8E568191Q36394177-58EFA35A-8495-4C7F-B151-CD8BEF256E11Q36636763-4263E990-2670-41AE-88E6-65342EAE74A2Q37204894-48766431-BEEA-477F-AF7E-B5AADCB13EC9Q37229742-9EC55747-38E0-4E98-B2B7-CB3F38EFDA72Q37293872-A590667E-63FA-41A8-AEDE-A291AA0D4457Q38363794-D7E71FCB-2601-4299-B400-F463860C174BQ38574514-8686F50F-C2A1-456E-928C-71C18BBB6A98Q38621582-7178A36F-A27C-44E6-9977-062AF01736F5Q38767468-5CB57C32-9630-4E53-8060-B50A0EA43D0EQ38990899-83732184-5B33-4BD1-BFB0-33ED2B3CDF12Q40107672-9F118F95-1B00-4D4D-BE41-42C5E5A63D66Q40309267-2432F3B0-BEC0-440E-9420-150146BC326DQ40781713-0EE50200-C259-4EE9-8F2A-052F4593BB50Q41003711-9D2AF1F4-0F68-4083-B22F-976A182A3270Q41517191-2F20F4B0-5581-40A7-B31A-5B48DB69A0D7Q42373425-5FFC14DC-F7C0-48A2-B964-5110A7E29525Q47553632-479F382D-C492-4B11-A382-0298D087FDC8Q52337140-2E65BA94-B052-4293-91B2-B6933683B14EQ58788228-08FB964C-95A1-41CA-8DAF-B3B5D1B72A67
P2860
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@en
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@nl
type
label
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@en
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@nl
prefLabel
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@en
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@nl
P2093
P2860
P50
P1433
P1476
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
@en
P2093
Angelique KanyKany Luabeya
Erica Smit
Hassan Mahomed
Hennie Geldenhuys
Jane E Hughes
Michele Tameris
Samantha Vermaak
P2860
P304
P356
10.1371/JOURNAL.PONE.0087340
P407
P577
2014-02-03T00:00:00Z